What is a stock summary page? Click here for an overview.
Business Description
TWi Biotechnology Inc
ISIN : TW0006610009
Description
TWi Biotechnology Inc is a clinical-stage biopharmaceutical company based in Taiwan. It is engaged in the development of new drugs for unmet medical needs, particularly in the diseases associated with innate immunity. The pipeline products of the company comprise AC-201, AC-203, and AC-701.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 11.25 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | -0.1 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -210.8 | |||||
3-Year EPS without NRI Growth Rate | -104.2 | |||||
3-Year FCF Growth Rate | -24.5 | |||||
3-Year Book Growth Rate | -20.4 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 51.59 | |||||
9-Day RSI | 46.87 | |||||
14-Day RSI | 44.84 | |||||
3-1 Month Momentum % | -8 | |||||
6-1 Month Momentum % | -5.6 | |||||
12-1 Month Momentum % | 5.86 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.93 | |||||
Quick Ratio | 2.93 | |||||
Cash Ratio | 2.89 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.7 | |||||
Shareholder Yield % | -0.69 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -65.01 | |||||
ROA % | -52.65 | |||||
ROIC % | -240.38 | |||||
3-Year ROIIC % | 2082.81 | |||||
ROC (Joel Greenblatt) % | -1981.09 | |||||
ROCE % | -63.19 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 5.64 | |||||
Price-to-Tangible-Book | 6.94 | |||||
EV-to-EBIT | -4.96 | |||||
EV-to-EBITDA | -5.28 | |||||
EV-to-FCF | -5.16 | |||||
Price-to-Net-Current-Asset-Value | 8.88 | |||||
Price-to-Net-Cash | 9.11 | |||||
Earnings Yield (Greenblatt) % | -20.14 | |||||
FCF Yield % | -15.93 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TWi Biotechnology Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil NT$) | |||
EPS (TTM) (NT$) | -1.787 | ||
Beta | 0.33 | ||
3-Year Sharpe Ratio | 0.07 | ||
3-Year Sortino Ratio | 0.14 | ||
Volatility % | 31.73 | ||
14-Day RSI | 44.84 | ||
14-Day ATR (NT$) | 0.770437 | ||
20-Day SMA (NT$) | 10.995198 | ||
12-1 Month Momentum % | 5.86 | ||
52-Week Range (NT$) | 8.96 - 15.587559 | ||
Shares Outstanding (Mil) | 92.2 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
TWi Biotechnology Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
TWi Biotechnology Inc Stock Events
Event | Date | Price (NT$) | ||
---|---|---|---|---|
No Event Data |
TWi Biotechnology Inc Frequently Asked Questions
What is TWi Biotechnology Inc(ROCO:6610)'s stock price today?
The current price of ROCO:6610 is NT$10.75. The 52 week high of ROCO:6610 is NT$15.59 and 52 week low is NT$8.96.
When is next earnings date of TWi Biotechnology Inc(ROCO:6610)?
The next earnings date of TWi Biotechnology Inc(ROCO:6610) is .
Does TWi Biotechnology Inc(ROCO:6610) pay dividends? If so, how much?
TWi Biotechnology Inc(ROCO:6610) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |